Cargando…
The lung in amyloidosis
Amyloidosis is a disorder caused by misfolding of autologous protein and its extracellular deposition as fibrils, resulting in vital organ dysfunction and eventually death. Pulmonary amyloidosis may be localised or part of systemic amyloidosis. Pulmonary interstitial amyloidosis is symptomatic only...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488920/ https://www.ncbi.nlm.nih.gov/pubmed/28877975 http://dx.doi.org/10.1183/16000617.0046-2017 |
_version_ | 1784792768685539328 |
---|---|
author | Milani, Paolo Basset, Marco Russo, Francesca Foli, Andrea Palladini, Giovanni Merlini, Giampaolo |
author_facet | Milani, Paolo Basset, Marco Russo, Francesca Foli, Andrea Palladini, Giovanni Merlini, Giampaolo |
author_sort | Milani, Paolo |
collection | PubMed |
description | Amyloidosis is a disorder caused by misfolding of autologous protein and its extracellular deposition as fibrils, resulting in vital organ dysfunction and eventually death. Pulmonary amyloidosis may be localised or part of systemic amyloidosis. Pulmonary interstitial amyloidosis is symptomatic only if the amyloid deposits severely affect gas exchange alveolar structure, thus resulting in serious respiratory impairment. Localised parenchymal involvement may be present as nodular amyloidosis or as amyloid deposits associated with localised lymphomas. Finally, tracheobronchial amyloidosis, which is usually not associated with evident clonal proliferation, may result in airway stenosis. Because the treatment options for amyloidosis are dependent on the fibril protein type, the workup of all new cases should include accurate determination of the amyloid protein. Most cases are asymptomatic and need only a careful follow-up. Diffuse alveolar-septal amyloidosis is treated according to the underlying systemic amyloidosis. Nodular pulmonary amyloidosis is usually localised, conservative excision is usually curative and the long-term prognosis is excellent. Tracheobronchial amyloidosis is usually treated with bronchoscopic interventions or external beam radiation therapy. |
format | Online Article Text |
id | pubmed-9488920 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-94889202022-11-14 The lung in amyloidosis Milani, Paolo Basset, Marco Russo, Francesca Foli, Andrea Palladini, Giovanni Merlini, Giampaolo Eur Respir Rev Reviews Amyloidosis is a disorder caused by misfolding of autologous protein and its extracellular deposition as fibrils, resulting in vital organ dysfunction and eventually death. Pulmonary amyloidosis may be localised or part of systemic amyloidosis. Pulmonary interstitial amyloidosis is symptomatic only if the amyloid deposits severely affect gas exchange alveolar structure, thus resulting in serious respiratory impairment. Localised parenchymal involvement may be present as nodular amyloidosis or as amyloid deposits associated with localised lymphomas. Finally, tracheobronchial amyloidosis, which is usually not associated with evident clonal proliferation, may result in airway stenosis. Because the treatment options for amyloidosis are dependent on the fibril protein type, the workup of all new cases should include accurate determination of the amyloid protein. Most cases are asymptomatic and need only a careful follow-up. Diffuse alveolar-septal amyloidosis is treated according to the underlying systemic amyloidosis. Nodular pulmonary amyloidosis is usually localised, conservative excision is usually curative and the long-term prognosis is excellent. Tracheobronchial amyloidosis is usually treated with bronchoscopic interventions or external beam radiation therapy. European Respiratory Society 2017-09-06 /pmc/articles/PMC9488920/ /pubmed/28877975 http://dx.doi.org/10.1183/16000617.0046-2017 Text en Copyright ©ERS 2017. https://creativecommons.org/licenses/by-nc/4.0/ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
spellingShingle | Reviews Milani, Paolo Basset, Marco Russo, Francesca Foli, Andrea Palladini, Giovanni Merlini, Giampaolo The lung in amyloidosis |
title | The lung in amyloidosis |
title_full | The lung in amyloidosis |
title_fullStr | The lung in amyloidosis |
title_full_unstemmed | The lung in amyloidosis |
title_short | The lung in amyloidosis |
title_sort | lung in amyloidosis |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488920/ https://www.ncbi.nlm.nih.gov/pubmed/28877975 http://dx.doi.org/10.1183/16000617.0046-2017 |
work_keys_str_mv | AT milanipaolo thelunginamyloidosis AT bassetmarco thelunginamyloidosis AT russofrancesca thelunginamyloidosis AT foliandrea thelunginamyloidosis AT palladinigiovanni thelunginamyloidosis AT merlinigiampaolo thelunginamyloidosis AT milanipaolo lunginamyloidosis AT bassetmarco lunginamyloidosis AT russofrancesca lunginamyloidosis AT foliandrea lunginamyloidosis AT palladinigiovanni lunginamyloidosis AT merlinigiampaolo lunginamyloidosis |